<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR814.html">Part 814
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 814.104  Original applications.
                            </h3>
                            <p class="depth1"><em>(a)</em> United States applicant or representative. The applicant or an  authorized representative shall sign the HDE. If the applicant does not  reside or have a place of business within the United States, the HDE  shall be countersigned by an authorized representative residing or  maintaining a place of business in the United States and shall identify  the representative's name and address.</p><p class="depth1"><em>(b)</em> Contents. Unless the applicant justifies an omission in  accordance with paragraph (d) of this section, an HDE shall include:</p><p class="depth2"><em>(1)</em> A copy of or reference to the determination made by FDA's Office  of Orphan Products Development (in accordance with Sec. 814.102) that  the device qualifies as a HUD;</p><p class="depth2"><em>(2)</em> An explanation of why the device would not be available unless  an HDE were granted and a statement that no comparable device (other  than another HUD approved under this subpart or a device under an  approved IDE) is available to treat or diagnose the disease or  condition. The application also shall contain a discussion of the risks  and benefits of currently available devices or alternative forms of  treatment in the United States;</p><p class="depth2"><em>(3)</em> An explanation of why the probable benefit to health from the  use of the device outweighs the risk of injury or illness from its use,  taking into account the probable risks and benefits of currently  available devices or alternative forms of treatment. Such explanation  shall include a description, explanation, or theory of the underlying  disease process or condition, and known or postulated mechanism(s) of  action of the device in relation to the disease process or condition;</p><p class="depth2"><em>(4)</em> All of the information required to be submitted under Sec.  814.20(b), except that:</p><p class="depth3"><em>(i)</em> In lieu of the summaries, conclusions, and results from clinical  investigations required under Sec. Sec. 814.20(b)(3)(v)(B), (b)(3)(vi),  and (b)(6)(ii), the applicant shall include the summaries, conclusions,  and results of all clinical experience or investigations (whether  adverse or supportive) reasonably obtainable by the   applicant that are relevant to an assessment of the risks and probable  benefits of the device; and</p><p class="depth3"><em>(ii)</em> In addition to the proposed labeling requirement set forth in  Sec. 814.20(b)(10), the labeling shall bear the following statement:  Humanitarian Device. Authorized by Federal law for use in the [treatment  or diagnosis] of [specify disease or condition]. The effectiveness of  this device for this use has not been demonstrated;</p><p class="depth2"><em>(5)</em> The amount to be charged for the device and, if the amount is  more than $250, a report by an independent certified public accountant,  made in accordance with the Statement on Standards for Attestation  established by the American Institute of Certified Public Accountants,  or in lieu of such a report, an attestation by a responsible individual  of the organization, verifying that the amount charged does not exceed  the costs of the device's research, development, fabrication, and  distribution. If the amount charged is $250 or less, the requirement for  a report by an independent certified public accountant or an attestation  by a responsible individual of the organization is waived; and</p><p class="depth2"><em>(6)</em> Information concerning pediatric uses of the device, as required  by Sec. 814.20(b)(13).</p><p class="depth1"><em>(c)</em> Omission of information. If the applicant believes that certain  information required under paragraph (b) of this section is not  applicable to the device that is the subject of the HDE, and omits any  such information from its HDE, the applicant shall submit a statement  that identifies and justifies the omission. The statement shall be  submitted as a separate section in the HDE and identified in the table  of contents. If the justification for the omission is not accepted by  the agency, FDA will so notify the applicant.</p><p class="depth1"><em>(d)</em> Address for submissions and correspondence. Copies of all  original HDEs amendments and supplements, as well as any correspondence  relating to an HDE, must be sent or delivered to the following:</p><p class="depth2"><em>(1)</em> For devices regulated by the Center for Devices and Radiological  Health, send to Document Mail Center, 10903 New Hampshire Ave., Bldg.  66, rm. G609, Silver Spring, MD 20993-0002.</p><p class="depth2"><em>(2)</em> For devices regulated by the Center for Biologics Evaluation and  Research, send this information to the Document Control Center (HFM-99),  Center for Biologics Evaluation and Research, Food and Drug  Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852- 1448.</p><p class="depth2"><em>(3)</em> For devices regulated by the Center for Drug Evaluation and  Research, send this information to the Central Document Control Room,  Center for Drug Evaluation and Research, Food and Drug Administration,  5901-B Ammendale Rd., Beltsville, MD 20705-1266.  [61 FR 33244, June 26, 1996, as amended at 63 FR 59220, Nov. 3, 1998; 73  FR 49942, Aug. 25, 2008; 75 FR 20915, Apr. 22, 2010; 79 FR 1740, Jan.  10, 2014]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
